Cardinal Health controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile11 entries
2024
Additional opioid-related settlements
The referenced material reports settlements with health plans and third-party payers, as well as a separate settlement with the City of Baltimore. The reported amounts were $92.7 million and $152.5 million respectively.
2022
Shareholder derivative settlement
The referenced material reports a $124 million settlement of a derivative action brought on behalf of shareholders in connection with opioid-related allegations.
2021
Multistate opioid settlement
Cardinal agreed to participate in a settlement with other pharmaceutical companies resolving thousands of opioid-related lawsuits. The referenced material identifies Cardinal's share as $6.4 billion over 18 years and states that the company did not admit wrongdoing.
2021
New York reaches $1.1 billion opioid settlement with distributors
Settlement
New York agreed to a $1.1 billion settlement with Cardinal Health, McKesson and AmerisourceBergen over claims that they helped fuel the opioid epidemic. The agreement requires the distributors to create a clearinghouse of opioid shipments to help flag suspicious orders.
Source excerpt
The agreement also requires the distributors to create a clearinghouse of their opioid shipments to help flag suspicious orders.
New York has agreed to a $1.1 billion settlement with three of the nation’s largest drug distributors — Cardinal Health, McKesson and Amerisource Bergen — over claims they helped fuel the opioid epidemic.
2020
Oklahoma sues opioid distributors
Lawsuit filed
In a lawsuit filed by Oklahoma Attorney General Mike Hunter, Cardinal Health, McKesson and AmerisourceBergen were named as defendants. The suit alleged that the companies distributed an oversupply of opioids into Oklahoma. The report describes the companies' liability as alleged and does not establish it. The filing is presented as an allegation by the state's attorney general rather than a finding of wrongdoing.
Oklahoma Attorney General Mike Hunter filed a lawsuit against Cardinal Health, McKesson and AmerisourceBergen, alleging that the companies distributed an oversupply of opioids into Oklahoma. The companies' liability is alleged, not established in the report.
Stated objective. The suit aims to hold defendants civilly liable for the alleged devastation caused by their facilitation of the illegal opioids market in Michigan.
Company response
Denial — McKesson
McKesson said in a statement Monday that “any suggestion that (the company) drove demand for opioids in this country reflects a fundamental misunderstanding and mischaracterization of our role as a distributor.”
Source excerpt
Oklahoma Attorney General Mike Hunter on Monday brought a lawsuit against three distributors of opioids
Hunter filed the lawsuit in Cleveland County District Court against Cardinal Health Inc., McKesson Corp. and AmerisourceBergen Corp.
The lawsuit said the defendants “distributed what can only be called a major oversupply of opioids into Oklahoma.”
2019
Opioid-crisis litigation
Cardinal was named in lawsuits alleging that pharmaceutical distributors' practices contributed to opioid over-supply and diversion in the United States.
2019
Four drug companies settle Ohio opioid lawsuit
Settlement
In an opioid lawsuit brought by Summit and Cuyahoga counties in Ohio, AmerisourceBergen, Cardinal Health, McKesson, and Teva reached a $260 million settlement before the scheduled federal trial. The companies stated that the settlement did not constitute an admission of fault for opioid addiction and abuse.
Company response
Denial — 美源伯根公司、卡地纳健康集团和麦克森公司
当日，上述三家药品分销商在一份联合声明中称，和解并不意味着他们有过错。
Source excerpt
和解金额总价为2.6亿美元。
四家大型药企21日宣布，与美国俄亥俄州的两个郡政府就阿片类诉讼案达成和解协议
近年来，包括上述郡县的不少美国地方政府都在就阿片类药物成瘾和滥用问题对药企提起诉讼
2012
Lakeland facility oxycodone suspension
The DEA suspended the Lakeland facility's controlled-substance distribution license over alleged excessive purchases by Florida pharmacies, particularly involving oxycodone. A federal court upheld the suspension on an imminent-danger rationale, and Cardinal later accepted a two-year restriction.
2008
DEA controlled-substance settlement
Cardinal agreed to pay civil penalties after DEA allegations that it failed to report suspicious hydrocodone orders. Distribution facilities faced temporary restrictions, including a suspension involving the Lakeland, Florida facility.
2006
Alaris SE infusion-pump FDA action
The FDA seized approximately 1,300 Alaris SE infusion pumps, and Cardinal stopped producing the device. The company later entered into consent and compliance agreements addressing product safety and manufacturing procedures.
2004
Accounting restatements
Cardinal announced plans to restate results for several earlier fiscal periods following an accounting review and an ongoing federal investigation. Later adjustments reclassified and restated portions of fiscal 2004 and prior consolidated financial statements.